sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis
Abstract:OBJECTIVE : To detect the value of sICAM-1 in the diagnosis and follow-up of treatment of tuberculosis.
DESIGN : sICAM-1 levels were evaluated before and after treatment in 30 patients with pulmonary tuberculosis, only before treatment in five patients with pneumonia, five with lung cancer, and five with bronchiectasis, and in 10 healthy volunteers.
RESULTS : sICAM-1 levels were as follows: 436.2 ± 194.4 ng/ml in patients with pulmonary tuberculosis, 274 ± 32.1 ng/ml in lung cancer patients, 268 ± 41.9 ng/ml in bronchiectasis patients, 199.6 ± 43.1 ng/ml in pneumonia patients, and 146.5 ± 20.2 ng/ml in healthy individuals. sICAM-1 levels of tuberculosis cases before treatment were higher than in both the healthy group and in all the other groups. The levels in the healthy group were lower than in all other groups.
CONCLUSION : The cut-off point (298 ng/ml) obtained by adding the standard deviation to the mean sICAM-1 value of patients without tuberculosis had 83.3% sensitivity, 86.6% specificity and 84.4% accuracy in differentiating pulmonary tuberculosis from other pulmonary diseases. sICAM-1 can be used as an auxiliary marker in the diagnosis of pulmonary tuberculosis.
Document Type: Regular Paper
Publication date: February 1, 2002
The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- ingentaconnect is not responsible for the content or availability of external websites